ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck KGaA Buys Into Threshold Cancer Drug

by Lisa M. Jarvis
February 13, 2012 | APPEARED IN VOLUME 90, ISSUE 7

Merck KGaA will pay Threshold Pharmaceuticals $25 million up front and up to $525 million in milestones for access to the cancer treatment TH-302. Merck will also cover 70% of the development costs for TH-302, a small molecule that is activated in tumor cell environments where the oxygen concentration is low. A Phase III trial testing the compound in soft-tissue sarcoma is under way, and Threshold expects to reveal data from a Phase II trial in pancreatic cancer later this month. Threshold retains an option to jointly sell the drug in the U.S.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment